Literature DB >> 6811355

Pharmacokinetics of intravenous glibenclamide investigated by a high performance liquid chromatographic assay.

H J Rogers, R G Spector, P J Morrison, I D Bradbrook.   

Abstract

A simple high performance liquid chromatographic assay for the determination of plasma glibenclamide concentrations is described. This resolved glibenclamide from normal plasma constituents. The calibration curve of the assay was linear over the range 10-500 microgram/l and the minimum level of detection was 2 microgram/l. Within-assay coefficients of variation were 11.6% (20 microgram/l); 5.3% (50 microgram/l); 6.8% (100 microgram/l); between-assay coefficients of variation were 8.4% (20 microgram/l); 4.7% (50 microgram/l) and 7.4% (100 microgram/l). The assay was used to study the pharmacokinetics of a 1 mg intravenous dose of glibenclamide in eight normal subjects. The mean half-life was found to be 1.47 +/- 0.42 h (SD) and no evidence for a non-linear beta-phase or slowly equilibrating 'deep' compartment was found although this could not be rigorously excluded. The mean systemic drug clearance was 78 +/- 29 ml X h-1 X kg-1 and the apparent volume of distribution in the beta-phase was 155 +/- 44 ml/kg. The median time of maximum response of plasma immunoreactive insulin was 25 min and the median time of maximum blood glucose response was 53 min. No correlation could be found between the pharmacokinetics of glibenclamide and these responses in fasted normal individuals.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6811355     DOI: 10.1007/bf00257728

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  12 in total

1.  Interacting effects of sulfonylureas and glucose on cyclic AMP metabolism and insulin release in pancreatic islets of the rat.

Authors:  V Grill; E Cerasi
Journal:  J Clin Invest       Date:  1978-05       Impact factor: 14.808

2.  Metabolism and kinetics of the hypoglycemic agent glipizide in man--comparison with glibenclamide.

Authors:  L M Fuccella; V Tamassia; G Valzelli
Journal:  J Clin Pharmacol New Drugs       Date:  1973 Feb-Mar

3.  [Resorption, excretion and metabolism after intravenous and oral administration of HB 419-14C in man].

Authors:  W Rupp; O Christ; W Heptner
Journal:  Arzneimittelforschung       Date:  1969-08

4.  Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen.

Authors:  P Trinder
Journal:  J Clin Pathol       Date:  1969-03       Impact factor: 3.411

5.  Pharmacokinetics--uses and abuses.

Authors:  P J Fell; M T Stevens
Journal:  Eur J Clin Pharmacol       Date:  1975-04-04       Impact factor: 2.953

6.  Behaviour of glibenclamide on repeated administration to diabetic patients.

Authors:  L Balant; G R Zahnd; F Weber; J Fabre
Journal:  Eur J Clin Pharmacol       Date:  1977       Impact factor: 2.953

7.  ESTRIP, a BASIC computer program for obtaining initial polyexponential parameter estimates.

Authors:  R D Brown; J E Manno
Journal:  J Pharm Sci       Date:  1978-12       Impact factor: 3.534

8.  [Studies on the bioavailability of glibenclamide].

Authors:  W Rupp; O Christ; W Fülberth
Journal:  Arzneimittelforschung       Date:  1972-02

9.  Radioimmunoassay of glibenclamide.

Authors:  K Kawashima; T Kuzuya; A Matsuda
Journal:  Diabetes       Date:  1979-03       Impact factor: 9.461

10.  Comparison of the pharmacokinetics of glipizide and glibenclamide in man.

Authors:  L Balant; J Fabre; G R Zahnd
Journal:  Eur J Clin Pharmacol       Date:  1975       Impact factor: 2.953

View more
  10 in total

1.  Pharmacokinetic and pharmacodynamic studies of glibenclamide in non-insulin dependent diabetes mellitus.

Authors:  S W Coppack; A F Lant; C S McIntosh; A V Rodgers
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

2.  The effect of hyperglycaemia on the absorption of glibenclamide in patients with non-insulin-dependent diabetes mellitus.

Authors:  A Hoffman; Y Fischer; D Gilhar; I Raz
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

3.  Hypoglycemia associated with the use of fluoxetine.

Authors:  M A Deeg; E W Lipkin
Journal:  West J Med       Date:  1996-03

4.  Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide.

Authors:  D Hartmann; A Korn; M Komjati; G Heinz; P Haefelfinger; R Defoin; W K Waldhäusl
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

Review 5.  The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs.

Authors:  R E Ferner; S Chaplin
Journal:  Clin Pharmacokinet       Date:  1987-06       Impact factor: 6.447

6.  Sulphonylureas and hypoglycaemia.

Authors:  R E Ferner; H A Neil
Journal:  Br Med J (Clin Res Ed)       Date:  1988-04-02

7.  Comparison of antihyperglycemic effects of creatine and glibenclamide in type II diabetic patients.

Authors:  Boris Ročić; Ariana Znaor; Petra Ročić; David Weber; Marijana Vučić Lovrenčić
Journal:  Wien Med Wochenschr       Date:  2011-07-29

8.  Comparative dose-related time-action profiles of glibenclamide and a new non-sulphonylurea drug, AG-EE 623 ZW, during euglycaemic clamp in healthy subjects.

Authors:  F J Ampudia-Blasco; L Heinemann; R Bender; A Schmidt; T Heise; M Berger; A A Starke
Journal:  Diabetologia       Date:  1994-07       Impact factor: 10.122

9.  The pharmacokinetics and pharmacodynamics of 12 weeks of glyburide therapy in obese diabetics.

Authors:  L A Jaber; E J Antal; R L Slaughter; I R Welshman
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

10.  A radioimmunoassay for determination of glibenclamide and other sulfonylureas.

Authors:  W Heptner; M Badian; S Baudner; C Hellstern; R Irmisch; W Rupp; K Weimer; H Wissmann
Journal:  Pharm Res       Date:  1984-09       Impact factor: 4.200

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.